July 18, 2026 a 08:38 pm

REGN: Analysts Ratings - Regeneron Pharmaceuticals, Inc.

Historical Stock Grades

The latest data indicates a positive analyst outlook for Regeneron with significant buying interest. The ratings demonstrate no negative sentiment among analysts as of July 2026.

Rating	Count	Score
Strong Buy	5
Buy	16
Hold	8
Sell	0
Strong Sell	0

Sentiment Development

The overall sentiment has been stable with a consistent number of Strong Buy and Buy ratings. Recent months have not seen any downgrade in Sell ratings, indicating maintained confidence in REGN's performance.

• The number of Strong Buy ratings remains stable at 5 from previous months.
• Buy ratings have slightly decreased from 18 in May 2026 to 16, indicating a slight shift towards caution.
• No Sell or Strong Sell ratings show a lack of negative sentiment.

Percentage Trends

Evaluation of percentage distribution shows a decrease in Strong Buy ratings from 25% in March 2025 to approximately 14.3% in July 2026. Buy ratings have remained robust at around 45.7%. Observing the gradual adjustment can signal subtle shifts towards more conservative stances.

• Percentage of Hold ratings has remained relatively stable over recent months.
• There have been no new Sell or Strong Sell ratings, indicating sustained confidence.
• Over the past year, a slight decrease in Strong Buy recommendations reflects some cautiousness among analysts.

Latest Analyst Recommendations

The most recent analyst recommendations for Regeneron highlight consistent support, with several reaffirming their positions.

Date	New Recommendation	Last Recommendation	Publisher
2026-07-09	Overweight	Overweight	Piper Sandler
2026-07-08	Equal Weight	Equal Weight	Morgan Stanley
2026-07-07	Sector Perform	Sector Perform	RBC Capital
2026-07-07	Buy	Buy	Truist Securities
2026-07-07	Buy	Hold	Benchmark

Analyst Recommendations with Change of Opinion

A few analysts have modified their stances, indicating adjustments in their views on Regeneron's potential.

Date	New Recommendation	Last Recommendation	Publisher
2026-07-07	Buy	Hold	Benchmark
2026-05-18	Market Perform	Outperform	Leerink Partners
2026-05-18	Neutral	Buy	Citigroup
2026-01-07	Buy	Underperform	B of A Securities
2025-12-03	Equal Weight	Overweight	Morgan Stanley

Interpretation

Analyst sentiment towards Regeneron is largely positive, with reinforced confidence evident through maintained ratings. However, recent shifts to 'Hold' or downgraded ratings remind investors to stay informed of market dynamics and REGN's strategic developments. The absence of 'Sell' suggestions indicates general stability but also demonstrates increased caution compared to past exuberance. This balance of cautious optimism suggests a healthy level of critical analysis among the analyst community.

Conclusion

Regeneron Pharmaceuticals is perceived favorably, sustaining its position as a promising biopharmaceutical candidate. The company's advancements and collaborations continue to underpin its market strength. Nevertheless, analysts reveal a nuanced view; while growth potential is acknowledged, industry competition and dependency on clinical successes necessitate vigilance. In sum, while the analyst outlook is largely constructive, the intricate market landscape mandates ongoing evaluation of REGN's prospects.